Cancer Research and Treatment

Rachna Arora

1 Article

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets: Rachna Arora, Manju Sharma, Tausif Monif, Sunil Iyer; Cancer Res Treat. 2016;48(3):1120-1129. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.436

Purpose
This study was designed to characterize the pharmacokinetic profile and to assess bioequivalence of the sponsor’s test formulation (imatinib mesylate 400 mg tablets) with an innovator product (Gleevec 400 mg tablets, Novartis Pharmaceuticals) under fed conditions, in adult patients of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) stabilized on imatinib mesylate 400 mg. In addition, the aim of this study was to monitor the safety profile of investigational medicinal products (IMPs).
Materials and Methods
A multicenter, randomized, open label, two-period, crossover, single dose bioequivalence study was designed for conduct under fed conditions in 42 adult Ph+ CML patients already stabilized on imatinib 400 mg tablets. Pharmacokinetic parameters T_max, C_max, and AUC_0-24 were calculated using a non-compartmental model on validated WinNonlin software. Validated SAS software was used for statistical evaluation of data. The safety profile of investigational products was monitored during the course of study by applying a clinical process for recording observed untoward effects postadministration of investigational products.
Results
The 90% confidence intervals for the test/reference mean ratios of the ln-transformed PK variables C_max (99.0%) and AUC_0-24 (99.2%) were within an acceptable range of 80%-125%, as per bioequivalence assumptions. Both formulations were well tolerated after oral administration of IMPs.
Conclusion
The test product was found to be bioequivalent and safe, and thus can be used interchangeably in clinical practice.

Citations

Citations to this article as recorded by

Glivec to generic imatinib switch: in vitro comparative dissolution assessment, bioequivalence, safety, and tolerability of 400 mg imatinib tablets in healthy volunteers
Samir Das, Saurav Sarkar, Ranabir Sahu, Tarun Kumar Dua, Paramita Paul, Gouranga Nandi
RSC Pharmaceutics.2025;[Epub] CrossRef
Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study
Xiaoxing Huang, Yiwei Liu, Jie Chen, Heng Zheng, Yufeng Ding, Zheng He
The Journal of Clinical Pharmacology.2023; 63(12): 1438. CrossRef
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan, Ahmet Emre Eşkazan
Blood Advances.2021; 5(17): 3344. CrossRef
Challenges in Chronic Myeloid Leukemia Management in South America
Katia B. Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A. M. Funke, Virginia Abello Polo
Current Hematologic Malignancy Reports.2021; 16(5): 440. CrossRef
Computational Approaches in Preclinical Studies on Drug Discovery and Development
Fengxu Wu, Yuquan Zhou, Langhui Li, Xianhuan Shen, Ganying Chen, Xiaoqing Wang, Xianyang Liang, Mengyuan Tan, Zunnan Huang
Frontiers in Chemistry.2020;[Epub] CrossRef
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, Maria Cristina Carraro, Mariella D'Adda, Francesca Lunghi, Michela Anghileri, Nicola Polverelli, Marianna Rossi, Mattia Bacciocchi,
BLOOD RESEARCH.2020; 55(3): 139. CrossRef
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
Iman Abou Dalle, Hagop Kantarjian, Jan Burger, Zeev Estrov, Maro Ohanian, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour, Jorge Cortes
Cancer Medicine.2019; 8(15): 6559. CrossRef
[ARTICLE WITHDRAWN] Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2018; 26(2): 297. CrossRef
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21
Xiangyu Zhou, Ping Yuan, Qi Liu, Zhiqiang Liu
Biomolecules & Therapeutics.2017; 25(5): 490. CrossRef

13,077 View
156 Download
8 Web of Science
9 Crossref

Author index